1:00 PM - 2:00 PM
Senior Product Manager Interview
Sarah Jenkins
Location
onsite, Milton Park, ENG, United Kingdom
Commitment
Full Time
Level
Director
Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response, boldly transforming cancer care because patient’s lives depend on it.
At Replimune, we live by our values:
People are at the center of everything we do, and when it comes to our employees, we make it personal. With a deep sense of purpose, a strong and evolving culture, a competitive and forward-looking total rewards program, everyone at Replimune has a unique opportunity to impact on the lives of patients, caregivers and themselves.
Join us, as we reshape the future.
The Associate Director - Process Development is responsible for managing the Process Development team at Replimune’s Milton Park facility. The Process Development team at the Milton Park facility collaborates with their PD colleagues in the US to characterize and improve process steps within the cGMP production processes by executing robust bench scale process experiments. The Process Development team at Milton Park is also responsible for the generation of materials to support other departments/studies (assay controls, assay buffers, preclinical / tox material, etc.). The Associate Director will ensure that all work is planned, performed, and reported in an efficient and compliant manner.
This position is based in our Milton Park location and typically has a 5-day on-site expectation.
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
We are an Equal Opportunity Employer.